The content on this site is intended for healthcare professionals only
Dr Suzanne Lentzsch talks to ecancer about her LINKER-MM1 trial.
The LINKER-MM1 Phase 1/2 clinical trial investigated 200 mg linvoseltamab, a bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Results showed a high objective response rate (71%), with deep and durable responses, including a ≥VGPR rate of 62% and a ≥CR rate of 46%.
Long-term follow-up indicated sustained efficacy, with a 12-month probability of maintaining response at 78% for all responders and 92% for patients with ≥CR.
The treatment was generally manageable, with the most common adverse events being cytokine release syndrome, neutropenia, and anemia.
The study highlights linvoseltamab's potential as a highly effective treatment for RRMM, including in high-risk subgroups.
KRdc as induction therapy shows improved OS for NDMM patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
